Preclinical evidence from different cancers (including OC) showed that hypomethylating agents can re-sensitize cancer cells to platinum in vitro and in murine models by restoring tumor-suppressor genes expression (such as RASSF1A, BRCA1, DAPK, OPCML, and hSulf-1) [119,120,121,122]. The gene discussed is DAPK1; the disease is cancer.